Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Daiichi Sankyo, Merck Expand Partnership To Co-Develop DLL3 Targeting T-Cell Engager MK-6070

Author: Benzinga Newsdesk | August 06, 2024 06:50am

Agreement builds on and complements Daiichi Sankyo and Merck's shared commitment to develop novel medicines for patients with cancer
Daiichi Sankyo and Merck to co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights

Posted In: DSNKY MRK